Septerna (NASDAQ:SEPN) Trading Up 8.4% – Here’s What Happened

Septerna, Inc. (NASDAQ:SEPN)’s share price traded up 8.4% during mid-day trading on Monday . The stock traded as high as $26.43 and last traded at $26.31. 52,213 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 337,603 shares. The stock had previously closed at $24.28.

Analysts Set New Price Targets

A number of research firms have issued reports on SEPN. Cantor Fitzgerald assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price objective on the stock. TD Cowen began coverage on Septerna in a report on Tuesday, November 19th. They set a “buy” rating for the company. Wells Fargo & Company initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 price target on the stock. Finally, JPMorgan Chase & Co. initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price objective for the company.

Septerna Stock Down 4.4 %

The business has a fifty day simple moving average of $23.66.

Insider Activity at Septerna

In related news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of Septerna stock in a transaction dated Monday, October 28th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the completion of the acquisition, the insider now directly owns 6,215,591 shares of the company’s stock, valued at $111,880,638. The trade was a 6.34 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.